X
Details:
Cannabis stimulates two receptors, cannabinoid receptor type 1 (CB1) and type 2 (CB2), within the endocannabinoid system. It is being investigated for multiple indications like post-surgical pain, depressive disorders, chronic headaches, alzheimer's agitation disorder, etc.
Lead Product(s): Tetrahydrocannabinol
Therapeutic Area: Neurology Product Name: Pink Kush
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 27, 2023
Chinaplas 2024
Not Confirmed
Contact SupplierDetails:
Pink Kush (delta-9 tetrahydrocannabinol) is a CB2/CB1 receptor partial agonist, which is approved in combination with Cannabigerol for the treatment of stress, pain and depression.
Lead Product(s): Tetrahydrocannabinol,Cannabigerol
Therapeutic Area: Psychiatry/Psychology Product Name: Pink Kush
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 27, 2023
Chinaplas 2024
Not Confirmed
Contact SupplierDetails:
Cannabis stimulates two receptors, cannabinoid receptor type 1 (CB1) and type 2 (CB2), within the endocannabinoid system. It is being investigated for multiple indications like post-surgical pain, depressive disorders, chronic headaches, alzheimer's agitation disorder, etc.
Lead Product(s): Cannabis-derived Therapy
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 31, 2023
Chinaplas 2024
Not Confirmed
Contact Supplier
Details:
Under the agreement, Avicanna and Medipharm intend to commercialize various formulations of Avicanna’s proprietary cannabinoid-based Self-Emulsifying Drug Delivery Systems (SEDDS) technology capsules for the Canadian and international markets.
Lead Product(s): Cannabidiol
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Avicanna
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 26, 2023
Chinaplas 2024
Not Confirmed
Contact SupplierDetails:
Cannabis stimulates two receptors, cannabinoid receptor type 1 (CB1) and type 2 (CB2), within the endocannabinoid system. It is being investigated for multiple indications like post-surgical pain, depressive disorders, chronic headaches, alzheimer's agitation disorder, etc.
Lead Product(s): Cannabidiol
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2023
Chinaplas 2024
Not Confirmed
Contact SupplierDetails:
Cannabis stimulates two receptors, cannabinoid receptor type 1 (CB1) and type 2 (CB2), within the endocannabinoid system. It is being investigated for multiple indications like post-surgical pain, depressive disorders, chronic headaches, alzheimer's agitation disorder, etc.
Lead Product(s): Cannabis-derived Therapy
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2023
Chinaplas 2024
Not Confirmed
Contact SupplierDetails:
MediPharmto design, manufacture and supply a liquid oral cannabis study drug for the Phase 2 Life’s end Benefits of cannabidiol and tetrahydrocannabinol (LiBBY) study, to be conducted in the U.S., across 20 sites, to treat hospice-eligible patients diagnosed with dementia and agitation.
Lead Product(s): Cannabidiol,Tetrahydrocannabinol
Therapeutic Area: Neurology Product Name: T2:C100
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: $16.0 million Upfront Cash: Undisclosed
Deal Type: Funding August 09, 2022
Chinaplas 2024
Not Confirmed
Contact SupplierDetails:
New CBG products include Advanced Formula, which is a CBG:CBD 1:2 oil, and Northbound, which is a high CBG vape cartridge with CBD inspired by The White and Appalachia strains.
Lead Product(s): Cannabigerol,Cannabidiol
Therapeutic Area: Neurology Product Name: CBG:CBD
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 05, 2022
Chinaplas 2024
Not Confirmed
Contact SupplierDetails:
Naturally derived oil and inhalable cannabigerol (cannabinoid) products added to MediPharm's wellness portfolio – the benefits of CBG without the effects of THC.
Lead Product(s): Cannabidiol,Cannabigerol
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 05, 2022
Chinaplas 2024
Not Confirmed
Contact SupplierDetails:
McMaster University researchers using MediPharm Labs’ CBD50 formula and CBD:THC 10:2 formulation, which has the same as MediPharm Labs’ CBD25, have received a No Objection Letter from Health Canada to begin recruiting human subjects for a placebo-controlled trial.
Lead Product(s): Cannabidiol
Therapeutic Area: Sleep Product Name: CBD50
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: McMaster University
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 31, 2021
Chinaplas 2024
Not Confirmed
Contact Supplier
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
KEY PRODUCTS
Medipharm is a full-service pharmaceutical company delivering high-quality, innovative Cannabis concentrate-based products & services.
